Domov › Glioblastom › Kalifornija › Los Angeles
Klinične študije za Glioblastom v Los Angeles, CA
24 študij za Glioblastom išče udeležence na lokacijah v Los Angeles in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
Vključevanje udeležencevFaza 3
- Kaiser Permanente, Los Angeles
- UCLA, Los Angeles
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
Vključevanje udeležencevFaza 3
- Keck Medicine of USC, Los Angeles
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Vključevanje udeležencevFaza 1/2
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Vključevanje udeležencevFaza 2/3
- Cedars Sinai - Samuel Oschin Comprehensive Cancer Institute, Los Angeles
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Vključevanje udeležencevFaza 2
- Cedars-Sinai Medical Center, Los Angeles
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Vključevanje udeležencevFaza 1/2
- Children's Hospital Los Angeles, Los Angeles
- University of California at Los Angeles, Los Angeles
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Vključevanje udeležencevFaza 1/2
- University of Southern California, Los Angeles
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
Vključevanje udeležencevFaza 1/2
- Cedars-Sinai Medical Center, Los Angeles
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
Vključevanje udeležencevFaza 1
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
Vključevanje udeležencevFaza 3
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Vključevanje udeležencevFaza 1/2
- UCLA Health Bowyer Oncology Center, Los Angeles
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Vključevanje udeležencevFaza 1
- University of California, Los Angeles (Data Collection Only), Los Angeles
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Vključevanje udeležencevFaza 3
- University of California, Los Angeles, Los Angeles
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
Vključevanje udeležencevFaza 2
- Cedars-Sinai Medical Center, Los Angeles
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
Vključevanje udeležencevFaza 2
- Cedars-Sinai Medical Center, Los Angeles
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Vključevanje udeležencevFaza 1
- University of California, Los Angeles (UCLA) Department of Medicine - Hematology/Oncology, Los Angeles
PH Sensitive MRI Based Resections of Glioblastoma
Vključevanje udeležencevFaza 1
- Ronald Reagan Medical Center, Los Angeles
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Vključevanje udeležencev
- Oncology Institute for Hope and Innovation, Los Angeles
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Vključevanje udeležencevFaza 1/2
- University of California Los Angeles, Los Angeles
Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients
Vključevanje udeležencevFaza 3
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma
Vključevanje udeležencev
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
Vključevanje udeležencevFaza 1/2
- University of California at Los Angeles, Los Angeles
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Cedars Sinai Medical Center, Los Angeles
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Vključevanje udeležencevFaza 2
- Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute, Los Angeles
Študije za Glioblastom v drugih mestih
- New York City, NY30 študij
- Boston, MA28 študij
- Houston, TX26 študij
- Durham, NC20 študij
- San Francisco, CA17 študij
- Chicago, IL15 študij
- Washington, DC15 študij
- Columbus, OH14 študij
- Miami, FL14 študij
- Rochester, MN13 študij
- Jacksonville, FL13 študij
- Aurora, CO12 študij
Druge študije v Los Angeles
- Nemalicelični pljučni rak87 študij
- Rak (vse vrste)74 študij
- Rak dojke73 študij
- Rak prostate61 študij
- Kolorektalni rak59 študij
- Metastatski rak57 študij
- Rak jajčnikov50 študij
- Rak pljuč45 študij
- Ploščatocelični karcinom glave in vratu42 študij
- Rak trebušne slinavke35 študij
- Rak endometrija34 študij
- Melanom34 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.